Laliberte R, Perregaux D, Svensson L, Pazoles C J, Gabel C A
Department of Immunology and Infectious Diseases, Pfizer, Inc., Central Research Division, Groton, CT 06340.
J Immunol. 1994 Sep 1;153(5):2168-79.
IL-1 beta is an important inflammatory mediator produced by monocytes and macrophages after LPS stimulation. In the absence of a secondary stimulus, however, little IL-1 beta is released into the medium. Previously, ATP was shown to promote the release and proteolytic maturation of IL-1 beta from LPS-stimulated murine peritoneal macrophages. Tenidap, a new anti-inflammatory and antiarthritic agent, inhibited the release and maturation of IL-1 beta induced in vitro by ATP treatment of murine peritoneal macrophages. Tenidap's inhibitory activity was mimicked by other agents that blocked anion transport, such as UK5099 and DIDS. In contrast, cyclooxygenase-inhibiting nonsteroidal anti-inflammatory drugs, such as piroxicam and naproxen, did not impair ATP-induced post-translational processing. Human monocytes responded to LPS to produce IL-1 beta, but externalized little of their newly synthesized cytokine. ATP at concentrations > or = 2 mM promoted IL-1 beta release from these cells. The degree to which the released cytokine was proteolytically processed to its biologically active 17-kDa species, however, depended on the pH of the medium; a greater processing efficiency was observed at slightly acidic (pH 6.9) values. Tenidap and other anion transport inhibitors effectively prevented the ATP response of cultured human monocytes. Likewise, LPS-stimulated human alveolar macrophages responded to ATP by releasing 17-kDa IL-1 beta, and tenidap inhibited this response. The ATP-induced release and maturation of IL-1 beta from human monocytes and macrophages, therefore, was suppressed by anion transport inhibitors, suggesting that anion conductance is a necessary component of the ATP-promoted externalization mechanism. In view of IL-1's importance as an inflammatory mediator, tenidap may demonstrate novel anti-inflammatory activities by virtue of its inhibition of the post-translational release and maturation of this cytokine.
白细胞介素-1β是脂多糖刺激后由单核细胞和巨噬细胞产生的一种重要炎症介质。然而,在没有二次刺激的情况下,很少有白细胞介素-1β释放到培养基中。此前,已证明三磷酸腺苷能促进脂多糖刺激的小鼠腹腔巨噬细胞释放白细胞介素-1β并使其进行蛋白水解成熟。替硝唑,一种新型抗炎和抗关节炎药物,抑制了三磷酸腺苷处理小鼠腹腔巨噬细胞后体外诱导的白细胞介素-1β的释放和成熟。替硝唑的抑制活性被其他阻断阴离子转运的药物所模拟,如UK5099和二碘水杨酸。相比之下,抑制环氧化酶的非甾体抗炎药,如吡罗昔康和萘普生,并不损害三磷酸腺苷诱导的翻译后加工。人单核细胞对脂多糖产生反应以产生白细胞介素-1β,但很少将新合成的细胞因子分泌到细胞外。浓度≥2 mM的三磷酸腺苷促进了这些细胞释放白细胞介素-1β。然而,释放的细胞因子被蛋白水解加工成其具有生物活性的17 kDa形式的程度取决于培养基的pH值;在略酸性(pH 6.9)值时观察到更高的加工效率。替硝唑和其他阴离子转运抑制剂有效地阻止了培养的人单核细胞的三磷酸腺苷反应。同样,脂多糖刺激的人肺泡巨噬细胞通过释放17 kDa白细胞介素-1β对三磷酸腺苷产生反应,而替硝唑抑制了这种反应。因此,阴离子转运抑制剂抑制了三磷酸腺苷诱导的人单核细胞和巨噬细胞释放白细胞介素-1β并使其成熟,这表明阴离子电导是三磷酸腺苷促进的细胞外分泌机制的必要组成部分。鉴于白细胞介素-1作为炎症介质的重要性,替硝唑可能因其抑制这种细胞因子的翻译后释放和成熟而表现出新型抗炎活性。